TY - JOUR
T1 - Oral gatifloxacin in outpatient community-acquired pneumonia
T2 - Results from TeqCES, a community-based, open-label, multicenter study
AU - Gotfried, Mark
AU - Quinn, Thomas C.
AU - Gothelf, Samantha
AU - Wikler, Matthew A.
AU - Webb, C. Douglas
AU - Nicholson, Susan C.
N1 - Funding Information:
Supported by Bristol-Myers Squibb Company. Rene Russo, PharmD and Kristen Von Seggern provided expert assistance in data analysis and study conduct.
PY - 2002/9
Y1 - 2002/9
N2 - Gatifloxacin is an 8-methoxy fluoroquinolone with broad activity against respiratory tract pathogens, including those commonly associated with community-acquired pneumonia (CAP). To evaluate the efficacy and safety of oral gatifloxacin 400 mg once daily for seven to 14 days, community-based physicians enrolled adult outpatients with confirmed or suspected CAP in a prospective, single-arm, open-label, noncomparative study. Of 1488 clinically evaluable patients with radiographically confirmed or clinically suspected CAP, 1417 (95.2%) were cured. All strains of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, the most commonly isolated pathogens, were susceptible to gatifloxacin. Penicillin nonsusceptibility was seen in 32.6% of S. pneumoniae isolates, and β-lactamase production was detected in H. influenzae (26.9%) and M. catarrhalis (88%) isolates. Clinical cure rates of 91%, 94%, and 92% were achieved in patients with S. pneumoniae, H. influenzae, and M. catarrhalis, respectively. All seven patients with fully penicillin-resistant S. pneumoniae (MIC ≥2 μg/ml) were cured. Gatifloxacin was well tolerated, with the most common drug-related adverse events being nausea (2.8%) and diarrhea (1.7%). Gatifloxacin is effective and well tolerated as empiric therapy for CAP in the outpatient community setting.
AB - Gatifloxacin is an 8-methoxy fluoroquinolone with broad activity against respiratory tract pathogens, including those commonly associated with community-acquired pneumonia (CAP). To evaluate the efficacy and safety of oral gatifloxacin 400 mg once daily for seven to 14 days, community-based physicians enrolled adult outpatients with confirmed or suspected CAP in a prospective, single-arm, open-label, noncomparative study. Of 1488 clinically evaluable patients with radiographically confirmed or clinically suspected CAP, 1417 (95.2%) were cured. All strains of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, the most commonly isolated pathogens, were susceptible to gatifloxacin. Penicillin nonsusceptibility was seen in 32.6% of S. pneumoniae isolates, and β-lactamase production was detected in H. influenzae (26.9%) and M. catarrhalis (88%) isolates. Clinical cure rates of 91%, 94%, and 92% were achieved in patients with S. pneumoniae, H. influenzae, and M. catarrhalis, respectively. All seven patients with fully penicillin-resistant S. pneumoniae (MIC ≥2 μg/ml) were cured. Gatifloxacin was well tolerated, with the most common drug-related adverse events being nausea (2.8%) and diarrhea (1.7%). Gatifloxacin is effective and well tolerated as empiric therapy for CAP in the outpatient community setting.
KW - Community-acquired pneumonia
KW - Gatifloxacin
KW - TeqCES
UR - http://www.scopus.com/inward/record.url?scp=0036743891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036743891&partnerID=8YFLogxK
U2 - 10.1016/S0732-8893(02)00447-9
DO - 10.1016/S0732-8893(02)00447-9
M3 - Article
C2 - 12376037
AN - SCOPUS:0036743891
SN - 0732-8893
VL - 44
SP - 85
EP - 91
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 1
ER -